Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2002 4
2003 8
2004 7
2005 8
2006 10
2007 8
2008 8
2009 8
2010 11
2011 10
2012 10
2013 5
2014 6
2015 9
2016 9
2017 4
2018 3
2020 6
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

125 results
Results by year
Filters applied: . Clear all
Page 1
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Vergote I, et al. Among authors: verheijen rh. N Engl J Med. 2010 Sep 2;363(10):943-53. doi: 10.1056/NEJMoa0908806. N Engl J Med. 2010. PMID: 20818904 Free article. Clinical Trial.
Sentinel node dissection is safe in the treatment of early-stage vulvar cancer.
Van der Zee AG, Oonk MH, De Hullu JA, Ansink AC, Vergote I, Verheijen RH, Maggioni A, Gaarenstroom KN, Baldwin PJ, Van Dorst EB, Van der Velden J, Hermans RH, van der Putten H, Drouin P, Schneider A, Sluiter WJ. Van der Zee AG, et al. Among authors: verheijen rh. J Clin Oncol. 2008 Feb 20;26(6):884-9. doi: 10.1200/JCO.2007.14.0566. J Clin Oncol. 2008. PMID: 18281661 Free article. Clinical Trial.
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, Jayson GC, Johnson N, Swart AM, Verheijen R, McCluggage WG, Perren T, Panici PB, Kenter G, Casado A, Mendiola C, Stuart G, Reed NS, Kehoe S; EORTC; MRC CHORUS study investigators. Vergote I, et al. Among authors: verheijen r. Lancet Oncol. 2018 Dec;19(12):1680-1687. doi: 10.1016/S1470-2045(18)30566-7. Epub 2018 Nov 6. Lancet Oncol. 2018. PMID: 30413383
Patient engagement in research on rare gynecological tumors.
Roze J, Groeneweg J, Monroe G, Fransen I, Gultekin M, Zweemer R, Verheijen RHM. Roze J, et al. Among authors: verheijen rhm. Int J Gynecol Cancer. 2020 Dec;30(12):2012-2014. doi: 10.1136/ijgc-2020-001555. Epub 2020 Jun 2. Int J Gynecol Cancer. 2020. PMID: 32487683 No abstract available.
Prognostic value of radiological recurrence patterns in ovarian cancer.
Roze JF, Veldhuis WB, Hoogendam JP, Verheijen RHM, Scholten RJPM, Zweemer RP. Roze JF, et al. Among authors: verheijen rhm. Gynecol Oncol. 2020 Jun;157(3):606-612. doi: 10.1016/j.ygyno.2020.03.003. Epub 2020 Mar 11. Gynecol Oncol. 2020. PMID: 32171567 Free article.
Ovarian carcinogenesis: an alternative hypothesis.
Piek JM, van Diest PJ, Verheijen RH. Piek JM, et al. Among authors: verheijen rh. Adv Exp Med Biol. 2008;622:79-87. doi: 10.1007/978-0-387-68969-2_7. Adv Exp Med Biol. 2008. PMID: 18546620 Review.
Notch signaling in serous ovarian cancer.
Groeneweg JW, Foster R, Growdon WB, Verheijen RH, Rueda BR. Groeneweg JW, et al. Among authors: verheijen rh. J Ovarian Res. 2014 Nov 4;7:95. doi: 10.1186/s13048-014-0095-1. J Ovarian Res. 2014. PMID: 25366565 Free PMC article. Review.
125 results